Elena Nikulina

Allogene Therapeutics presents interim futility analysis for ALPHA3 at SITC2026

Allogene Therapeutics presents interim futility analysis for ALPHA3 at SITC2026
Allogene shares ALPHA3 futility data

Allogene Therapeutics announced an interim futility analysis for its ALPHA3 allogeneic CART cell therapy program during SITC2026.

The company also outlined the continued expansion of its allogeneic CART product portfolio, aiming to improve patient access in cancer treatment and related areas. CEO Zachary Roberts, MD, PhD, delivered the update as part of ongoing efforts in advancing cell therapy innovation.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.